November 26, 2021
December 27, 2021
The purpose of this study is to assess the safety, drug levels, immunogenicity and preliminary efficacy of BMS-986213 (relatlimab/nivolumab fixed-dose combination) in Chinese participants with advanced solid tumors.
|Experimental: BMS-986213 Fixed Dose Combination
Specified dose on specified days
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com Inclusion Criteria: Presence of at least one lesion with measurable disease as defined by RECIST v1.1 criteria for response assessment Participants must have received, and then progressed, or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting, if such a therapy exists ECOG status of 0 or 1 Life expectancy of ≥ 12 weeks at the time of informed consent per Investigator assessment Exclusion Criteria: Participants with history of severe and/or life-threatening toxicity related to prior immune therapy (eg, anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) Participants with an active, known or suspected autoimmune disease Participants with primary CNS tumors Other protocol-defined inclusion/exclusion criteria apply
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: Clinical.Trials@bms.com
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb